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MOBILIZED PERIPHERAL BLOOD CONTAINS PRIMITIVE HEMATOPOI- 
ETIC CELLS THAT CAN BE ENUMERATED AND ISOLATED USING A 
FLUORESCENT SUBSTRATE FOR ALDEHYDE DEHYDROGENASE 
ACTIVITY 
Fallon, P.z; GelJtO,, T.~; Balber, A.s; Boul~vm'e, D/,  ffanssen, I V.1; 
Smilee, R. z;StoJwTs, R.2; Smith, C~ l. Department of l*zterdisciplinmy 
Oncologo~, lojCfi'tt Cancer Ce*lter, TaTnpa, FL; 2. Dzlke University 
Medical Center, Durham, NC; 3. StemCo Biomedical, Durham, NC. 
High dose therapy followed by autolog'ous or allogeneic trans- 
plantation with peripheral blood stem cells (PBSCs) has been used 
to treat patients with a variety of diseases. Selection of primitive 
stem cells and progenitors from PBSC collections is useful for 
reducing the transplant volume and decreasing the number of con- 
taminating tmnor cells or T-cells. We have developed a novel 
approach for enmnerating and enriching primitive mobilized 
peripheral blood cells that express high levels of the enzyme alde- 
hyde dehydrogenase (ALDH). Mobilized cells were stained with a 
fluorescent ALDH substrate, termed BODIPY-aminoacetaldehyde 
(BAAA), and then analyzed or sorted using flow cytometry. A pop- 
ulation of cells, termed SSCloALDHbr cells, was readily discrimi- 
nated and comprised amean of 3.1 +4.8% of the collected events. 
A mean of 73.4 +11.7% of the SSCloALDHbr population 
expressed CD34 and 56 + 24.5% of all the mobilized CD34+ cells 
resided within the SSCloALDHbr population. The SSCloALD- 
Hbr population was largely depleted of cells with mature pheno- 
types and enriched for cells with immature phenotypes. The BAAA 
staining procedure did not diminish the viability or clonogenic 
activity of hematopoietic progenitors and caused no toMcity to cells 
or animals in a variety of pre-clinical toxicology studies. Sorted 
SSCloALDHbr and SSCloALDHbr CD34+ cells were enriched 
for progenitors with the ability to 1) generate CFUs and LTC 
derived CFUs, 2) expand in primary and secondary LTCs and 3) 
generate multiple cell lineages. In order to test whether the num- 
ber of PBSC SSCloALDHbr cells would predict engraftment in
actual human transplants, the total number of SSCIoALDHbr cells 
infused per kg in 21 cancer patients who had undergone autoPBSC 
transplantation were compared to the times to an ANC>500 and a 
platelet count >20, 000 using a Cox proportional hazard analysis. 
The time to neutrophil and platelet engraftment were both highly 
correlated with the number of SSCloALDHbr cells/kg (p<0.015 
and 0.003 respectively) and the number of SSCloALDHbr CD34+ 
cells/kg (p<0.013 and 0.0016 respectively). In smnmary, PBSC 
SSCloALDHbr cells have the phenotypic and functional properties 
of primitive hematopoietic cells and their number correlates with 
short erm engraftment following autoPBSCT transplantation. 
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NORMAL AND NEOPLASTIC B CELLS ARE UNDULY SUSCEPTIBLE TO 
PHOTODYNAMIC CELL THERAPY 
Roy, D.C/; Dallaire, N J; Krosl, GJ; Autonia, B.S; Freeman, G.ff.~; Per- 
reazdt, C.S ; T 7illeneuve, L. s 1. Hematology-Immunolo©~, Hopital 3/Iaison- 
neuve-Rosemont, Monn'eal, QC, Cmzada; 2. Dana-Fro'bet Cancer Insti- 
tztte, Boston, [vIA; 3. Celmed BioScie~zces Inc., l~/lo*ztreal, QC, Canada. 
The favorable effect associated with the infusion of a graft 
purged of its neoplastic ells might be jeopardized by the con- 
comitant elimination of cell populations responsible for (1) the 
eradication of residual lymphoma cells, (2) the prevention of viral 
and fungal infections, and (3) rapid hematologic reconstitution 
post-transplantation. In previous studies, we have shown that 
TH9402, a rhodamine-derived photosensitizer, selectively elimi- 
nates activated T ceils, and spares resting T cells. Interestingly, P-
glycoprotein (Pgp) modulates TH9402-mediated cytotoxicity by 
extruding this photosensitizer from the intracellular milieu. The 
absence of Pgp expression in most NHL cells prompted us to 
evaluate photodynamic cell therapy (PDCT) with TH9402 for the 
selective limination of B-lineage lymphoma cells. To identify 
optimum treatment conditions, the uptake/retention ki etics and 
cytotoxicity profile of TH9402 were evaluated with B-lineage cell 
lines, NHL patient cells harboring or not a bcl-2/IgH rearrange- 
ment, and normal B lymphocytes. In clonogenic assays, more than 
4 logs of indolent bcl-2/IgH rearranged (RL and DHL-16) and 
aggressive (Namalwa nd Rail) NHL cell lines and patient (n=27) 
NHL cells were eradicated following PDCT using TH9402. 
Mthough normal B lymphocytes retained TH9402 in anmunts 
similar to T cells, as measured by flow-cytometry, PDCT elimi- 
nated 4 logs of B ceils but only 1 log of T lymphocytes, which 
were spared for imnmne reactivity. Importantly, PDCT condi- 
tions of maximum intensity that preserved more than 50% of 
CFU-GM, BFU-E and CFU-Mix colonies, and greater than 75% 
of LTC-IC progenitors for hematopoietic reconstitution, demon- 
strated lower levels of retention of TH9402 in CD34+ cells. The 
discrepancy between TH9402 retention levels and cytotoxicity 
indicates that the exquisite sensitivity of B lineage ceils to TH9402 
phototherapy must rely on a retention-independent mechanism of 
target cell elimination. The specificity" of TH0402 for B lympho- 
cytes indicates that this strategy should be evaluated for ex vivo 
purging of autologous tem cell grafts from patients with NHL 
and also for the treatment of autoimmune B cell disorders. 
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MOBILIZATION OF TYPE I AND TYPE 2 DENDRITIC CELLS BY GM- 
CSF ALONE OR IN COMBINATION WITH G-CSF 
Gao, H.; Korb/iug, M.; Lee, B.; Champ~in, R.; Reuben, ff.M. 
M.D.A1~de'rsmz Crower Center, Houston, TX. 
Dendritic cells (DC) are fire only antigen-presenting cells capa- 
ble of priming naive T cells with antigens. Generally, DC does 
not express lineage-specific markers (lineage negative), but express 
HLA-DR. There are two subsets of DC: one of lymphoid lineage 
that induces Thl-like responses and expresses CD11c (DC1) and 
another of myeloid lineage that induces Th2-1ike responses and 
expresses CD123 (DC2). Previous studies reported that G-CSF 
preferentially mobilized DC2, and not DC1, in nornral subjects. 
To determine the effect of GM-CSF alone or in combination with 
G-CSF on the mobilization of DC1 and DC2, we studied DC 
markers in 7 subjects received 10 mcg/kg/day of GM-CSF for 4 
days and another 5 subjects received 10 meg/ko'/day of GM-CSF 
and 10 mcg/kg/day of G-CSF for 4 days. Peripheral blood was 
obtained from all subjects before treatment and 24 hours after the 
final dose of the mobilization regimen. The numbers of DC1 and 
DC2 were determined by staining blood with lineage cocktail 
antibodies, anti-HLA-DR, anti-CD11c, and anti-CD123, and 
analyzed by 4 color flow cytometry. Compared with the number 
of total DC prior to treatment with G CSF plus GM-CSF, the 
post-treatment number of DC was significantly hip'her (32 +/- 6 
per mcl versus 143 +/- 35 per mel; p = 0.020). The increase in 
total DC post-mobilization with G-CSF and GM-CSF was due to 
a significant increase in DC2 (8 +/- 3 per mcl versus 37 +/- 19 per 
mcl; p = 0.046), and not in the number of DC1. By comparison, 
mobilization of DC, DC1, and DC2, with GM CSF alone was 
only marginal. The preferential expansion of DC2 by the combi- 
nation of G-CSF and GNI-CSF as with G-CSF alone may have 
important consequences on sensitization of the host and on the 
engraftumnt. 
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EFFECTIVENESS OF METRONIDAZOLE ON CYCLOSPORINE-INDUCED 
GINGIVIAL HVPERPLASIA IN BONE MARROW AND KIDNEY TRANS- 
PLANT PATIENTS:A PROSPECTIVE, DOUBLE-BLINDED CONTROLLED 
CLINICAL TRIAL 
Heshmat, ,4.; Najafi, I.; Mog,Oadmn, K.; h'awmi, M.; Ym~esiyan, 3'1.; 
Zohrevamt, P. Shariati Hospital, Teh~wz, Teh'raJz, bwz. 
Background:  Cyclosporine-induced gingival hyperplasia 
(CIGH) regression has been reported with some antibiotic thera- 
pies, especially Metronidazole and Azithromicine. Object: To 
evaluate the efficacy of metronidazole on CIGH regression, 
Method:  we performed a prospective double-blinded study on 22 
patients with CIGH, following kidney or bone marrow transplan- 
tation. None of the patients received calcimn-channel blockers or 
anticonvulsants. Other causes of gingival enlargement were ruled 
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out among our patients. Before being allocated into the study 
groups, the patients had undergone a course of dental treatment 
programs for three weeks in order to reduce the amount of super- 
imposed ental inflammation as mnch as possible. Thereafter, the 
patients were randomized into intervention and control groups. 
Metronidazole tablets 250 mg/TDS were given to the interven- 
tion group, while the control group received the same amount of 
placebo. Patients were examined by a blinded periodontologist, at 
clays 0, 7, 14, and 2 I, to determine the gingival overgrowth scores, 
Results: The two groups were identical in age, gender, cause of 
receiving cyclosporine (kidney or bone marrow transplantation), 
duration of receiving cyclosporine, plasma level of cyclosporine 
and gingival overgrowth scores. Gingival enlargement improved 
in 7 patients, of whom 6 were in our intervention group (54.5%). 
The response to reatment was different in two groups ignificant- 
ly (P= 0.03). No association was found between gender, cause of 
receiving cyclosporine, duration of receiving cyelosporine, plasma 
level of cyclosporine and gingival overgrowth scores variables and 
response to treatment. Conclusion: In conclusion, our findings 
suggest hat we can benefit the advantages of metronidazole 
administration i  CIGH. Mthough we think that higher doses of 
metronidazole in association with oral hygiene programs and den- 
tal treatment planning could show better esults in such patients. 
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RECOVERY OF LEUKOCYTES FROM CORD BLOOD UNITS AFTER CON- 
TROLLED RATE FREEZE IN DMSO AND CRYOPRESERVATION IN THE 
VAPOR PHASE OF LIQUID NITROGEN 
Latze, T.A.t; Buenviaje, J / ;  Phmkett, M/; Law, lO.2 1. Americmz Red 
C'ross fVestetvz Area Commu~ity Cord Blood Ba*zk, Pot'tla~M, OR; 
2. University of Califor*zia, Sa~z Diego, &'hool of 3iedieiTze, La ffolla, CA. 
American Red Cross, Western Area Community Cord Blood 
Bank has established a program to assure the quality of cryopre- 
served volunteer donor cord blood units (CBU). Recovery. (Rec) 
of leukocytes (WBC) and WBC viability after CBU thawing are 
important surrogate measures CBU quality. We determined tl~e 
Rec of WBC in cryopreserved CBU immediately post-thaw and 
after dilution and washing in Dextran 40/5% Albumin (D/A), 
which is widely employed. Methods: CBU were collected from 
consented volunteer donors. CBU that were eligible for trans- 
plant, but had less WBC than required by storage criteria (6 ES) 
were studied. CBU were processed within 48 hours by Rubin- 
stein's method. The CBU volume after addition of 10% DMSO 
was 25 ml. CBU were cryopreserved by controlled rate freezing 
and stored in vapor phase liquid nitrogen for up to I year. Twelve 
CBU selected for study were removed from storage and immedi- 
ately placed in a 37 C waterbath. After thawing, the CBU was 
maintained at 4 C and a sample was immediately removed to 
assess post-thaw WBC (% NC-Rec) and cell viability by Trypan 
blue dye exclusion (% TB-viable). The CBU was diluted over 2 
rain in 25 ml D/A, samples removed, then the CBU was diluted to 
100 ml in D/A. The CBU was centrifuged at 400 xG at 4 C and 
resuspended in 25 ml of D/A. WBC Rec and NC viability were 
assessed post-thaw, after the 1:1 dilution in D/A, and post wash 
and resuspension. I  separate experiments, the Rec of CD34-bear- 
ing cells was measured. Results: There was a median 22% loss of 
NC after thawing, and additional NC loss after dilution and wash 
ing. Post thaw trypan blue dye viability was slightly reduced. In 6 
separate xperiments he Rec of CD34+ cells was 107 + 31% after 
thawing and 106 -+ 33 after washing. Conclusions: Thawing of 
cryopreserved CBU was associatedwith loss of approximately 
22% of the total NC and reduction in overall cell viability. Fur- 
ther cell loss accompanied washing. Recovery of CD34 bearing 
cells was uperior to total NC. Hematopoietic progenitor growth 
in culture after CBU thawing was consistent with the above. 
 Time I Po  T, Po L  w !Post O,,Ll, oolPo t Po tW  W  h I 
t NCReci  Bv, b,o I  NCRoo I TBV, bleI NCR I' TBv' b 
] p 0.02 0.00- ] 0.019 ] 0.014 ] 0.001 ] 0.005 | 
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EX VIVO ENGINEERING OF PREVIOUSLY THAWED AND CRYOPRE- 
SERVED UMBILICAL CORD BLOOD (UCB) WITH INTERLEUKIN (IL)-2, 
IL-7, IL-12 AND ANTI-CD3 FOR EXPANSION OF CYTOTOXIC T LYM- 
PHOCYTES (CTL): PROMISING STRATEGY FOR ADOPTIVE CELLULAR 
IMMUNOTHERAPY (ACI) POST UCB TRANSPLANTATION(T) 
Cairo, M.S.; Ayello, J.; vat~ de Ven, C. Child'ren's Hospital ofNew 
York Presbyteriml, New York, NY. 
Limitations associated with using UCB as a source for ACI post 
UCBT includes the lack of donor immunoeffector cells from the 
original cryopreserved UCB unit and/or immaturity of CB cellular 
immunity. We have demonstrated that CTL can be selectively 
engineered and activated from fresh and cryopreserved and thawed 
(CT) aliquots of UCB (Robinson/Cairo et al, Exp Hem 30:245, 
2002). In this study we evaluated and compared the activation and 
NK and LAK cytotoxicity of UCB CTL  Thawed UCB aliquots 
were monocyte depleted (5 xl06 cells/ml) in serum-free (SF) AIM- 
V in 5% CO2 @ 37°C. Nonadherent cells (lxl06 cells/ml) were 
either cultured in SF AIM-V + anti-CD3 (50 ng/ml), IL-2 (5 
ng/ml), IL-7 (10 ng/ml) and IL-12 (10 ng/ml) (AB/CY) or in SF 
AIM-V alone for 48 hours @ 37°C in 5% CO2 or expanded, recry- 
opreserved and rethawed (TECT), or not expanded but recryopre- 
served, rethawed and subsequently expanded (TCTE). NK subsets 
were analyzed by flow cytometry and NK and LAK cytotoxicity by 
YVST- 1 methodology utilizing a 10:1 E:T ratio against K562 (NK) 
and Dandi (LAK), respectively. A significant enhancement i  NK 
cytotoxicity was seen when UCB cells were cultured in the AB/CY 
cocktail (p<0.001) when compared to media alone, but no differ- 
ence between the nrodalities (TE: 0.73+0.03 vs 0.16-+0.01; 
TECT:0.72_+0.03 vs 0.16+_0.01 and TCTE:  0.75+0.04 vs 
0.16-+0.01). Similarly, there was significant enhancement of LAK 
cytotoxcity with all modalities of AB/CY stimulation vs media 
alone (p<0.001) but no difference between modality (TE: 0.39-+0.01 
vs 0.26-+0.0l; TECT: 0.37-+0.008 vs0.23+_0.002; TCTE: 0.41_+0.01 
vs 0.20-+0.01). Furthermore, there was a signfificant increase in the 
CD3-/16+/56+ subset of TE, TECT and TCTE when compared 
to media alone (TE: 60.2-+1.24% vs 47.33-+0.55%, n=3, p<0.001; 
TECT:  60.67+2.4% vs 46.68-+1.3%, n=3, p<0.001; TCTE:  
60.7+-3.27% vs 45.45_+1.4%, n=3, p<0.001). These data suggest that 
previously cryopreserved an  thawed UCB aliquots may be engi- 
neered at time of UCB transplant, ex vivo expanded and activated 
for cytotofic (NK & LAK) potential and recryopreserved for later 
use for DLI post UCBT. Xenotransplant animal studies are under- 
way to examine the in vivo effects of this UCB CTL population. 
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ONCE AND TWICE FILGRASTIM FOR ALLOGENEIC PBSC MOBILIZATION 
Yuji, I(.1; Hamaki, T.e; Iiji~la, K. 2, Yosihcma, S.2; Imataki, 0.2; Koji- 
ma, R.2; Ueymna, j.2; ~smni, E.e; Mmo, F.2; JliitaJd, 1(.2; Mori, S. e 
1. ToT:a*mmon Hospital, Minato-ku TOI~O, Japing; 2. Japa,z Hema- 
tology and 07~cology Clinical Study Group, Bu,~kyo-ku TOIxTO, ffapan. 
Objective: To compare fficacy and safety in allogeneic periph- 
eral blood stem cell (PBSC) donors who received 400gg/m^2/day 
of filgrastim administered sl~bcutaneously once daily (Once-daily 
regimen) or in two-divided ose every 12 hours (Twice-daily regi- 
men). Design: An open-label, randomized, multicenter phase III 
trial. Patients: Between May 2001 and May 2002, 72 PBSC 
donors were enrolled in this study. Eligibility criteria was as fol- 
lows: Allogeneic PBSC donors to related patients aged between 16 
and 65 years, eligible for the criteria described in the Japan Soci- 
ety for Hematopoietic Cell Transplantation (JSHCI) guideline of 
PBSC harvest. Intervention: Donors were randomly assigned to 
receive 400btg/m^2 of G-CSF (filgrastim) subcutaneously once 
daily or in two-divided doses every 12 hours on 3 consecutive 
d~ys. PBSC was collected by leukapheresis u ing COBE Spectra 
on day 4. Main Outcome Measures: The primary endpoint of this 
study was CD34 positive cell dose per kg of donor's body weight 
collected by leukapheresis on day 4. Additional endpoints were 
total nucleated cell (TNC) counts in the leukapheresis products, 
total pain burden experienced by donor measured with area under 
curve (AUC) of visual analogue scale (VAS), and total dose of 
analgesic drugs. Safety endpoints: Incidence and severity of 
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